Giving Hope: Improving Care After Stem Cell Transplants for Blood Cancer Patients
NCT03970096 · RecruitingThis trial studies how to reduce graft versus host disease (GVHD) in patients with acute leukemia or myelodysplastic syndrome (MDS). GVHD happens when donor cells attack the recipient's body. The goal is to see which treatment works better to keep patients healthy after a stem cell transplant. Researchers are looking at two strategies to help manage this condition and improve outcomes for patients in remission.
Locations and contact
This trial is running at 3 locations in the United States. All of them are currently recruiting.
United States3 locations · 3 recruiting
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, WashingtonRecruiting
- Moffitt Cancer CenterTampa, FloridaRecruiting
- University of Pittsburgh Cancer Institute (UPCI)Pittsburgh, PennsylvaniaRecruiting
Who can join
Patients between 1 and 60 years old can join if they have acute leukemia or MDS and are suitable for a specific type of stem cell transplant. Both men and women can participate. The study team will check to see who qualifies to ensure safety and suitability.
What happens during the trial
Participants will be assigned to one of four groups by chance. Each group receives different treatments that may include chemotherapy, radiation, and donor stem cells. Some groups will get special medicines to help reduce the risk of GVHD. Everyone will have regular check-ups and tests to monitor their health throughout the trial.
The trial team
The trial is run by the Fred Hutchinson Cancer Center. Marie Bleakley is the principal investigator, and the National Cancer Institute collaborates with the team.
Important dates
The trial started on November 19, 2019, and is currently enrolling new participants. It is expected to finish by December 31, 2029.
Additional information
The trial's ID number is NCT03970096. This is a Phase 2 trial, which means it is looking at how well the treatment works and its safety. The trial is FDA-regulated and aims to enroll about 120 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →